Kornimate/medical-research-clean huggingface dataset:
insulin in treatment of diabetes mellitus with pregnancy

Conditions: Diabetes

Summary: the prevalence of diabetes melilites is rapidly increasing over years and consequently during pregnancy. in 2017, there were 21.3 million pregnant women who experienced hyperglycemia, of which 86.4% of them were diagnosed with gestational diabetes melilites. pregnancy in women with diabetes is associated with an intensification in adverse maternal, fetal and perinatal outcomes including spontaneous abortions, congenital malformations, preterm labor, and macrosomia. several studies have confirmed that poor glycemic control in women with either gestational, type 1 or type 2 diabetes during pregnancy is associated with poor pregnancy outcomes. in the same line, proper glycemic control before, early, and through all pregnancy markedly improves both maternal and fetal outcomes. insulin therapy is the standard treatment of diabetes melilites with the pregnancy if dietary control and exercise fail. however, insulin therapy has its difficulties like approaches to mimicking postprandial insulin release, providing adequate background insulin, balancing insulin dosage, food, activity, hypoglycemic episodes, overall glycemia. this is always a struggle for doctors and patients and much affecting their lifestyle


Eligibility criteria:
inclusion criteria: * age of 18 - 45 years old, * women with pre-gestational diabetes. * those who were under premixed insulin therapy prior to pregnancy. * women pregnant between 14 weeks up to 28 weeks of gestation exclusion criteria: * history of recurrent miscarriage * multiple pregnancies * chronic hypertension * severe heart, liver, and kidney disease. * women how got pregnant after assisted reproduction * those with advanced retinopathy, hypersensitivity to insulin. * women who developed bleeding in early pregnancy and those diagnosed to have any major anomaly during the first-trimester scan.
ideal sedation for stroke thrombectomy

Conditions: Ischemic Stroke

Summary: the ideal sedation for stroke thrombectomy (isst) registry will answer the key questions whether sedation with intubation and paralytics is feasible and whether it delays the time to recanalization in comparison with conscious sedation alone. as a pilot registry, it is anticipated to enroll 40 acute stroke patients requiring mechanical thrombectomy over 12-18 months. following enrollment, data will be collected prospectively from medical records and from patients' visits.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * suitable for intra-arterial treatment for acute stroke up to 8 hours from onset of symptoms * clinical equipoise for best mode of sedation exclusion criteria: * any known allergy to either proposed medication and its alternative * any patient that has been intubated prior to randomization * posterior circulation strokes * age ≤ 18 * pregnant female
flt3l in treating patients with metastatic colorectal cancer

Conditions: Colorectal Cancer; Metastatic Cancer

Summary: rationale: flt3l may stimulate a person's immune system and help kill tumor cells. purpose: phase i trial to study the effectiveness of flt3l given to patients before undergoing surgery to remove metastases from colorectal cancer.

objectives: i. evaluate the safety and feasibility of administering flt3 ligand to patients with hepatic metastases from colorectal cancer prior to surgical resection. outline: patients receive flt3 ligand subcutaneously for 14 days followed by 14 days of rest. this course of therapy may be repeated for a total of 3 courses. leukapheresis is performed on day 15 of the last course of flt3 ligand. patients undergo restaging and metastasis resection. patients are followed every 3 months for the first year, every 6 months for the second year, and yearly thereafter. projected accrual: this study will accrue 12 patients in 1 year.

Eligibility criteria:
disease characteristics: histologically confirmed metastatic colon cancer expressing carcinoembryonic antigen (cea) at least 50% of tumor cells must express cea with at least moderate intensity resectable hepatic metastases or other site of metastatic colon cancer that is resectable (e.g., lung metastases) patient characteristics: age: 18 and over performance status: karnofsky 70-100% life expectancy: at least 6 months hematopoietic: absolute neutrophil count at least 1000/mm3 absolute lymphocyte count at least 1000/mm3 hemoglobin at least 9 mg/dl platelet count at least 100,000/mm3 hepatic: bilirubin less than 2.0 mg/dl no hepatic disease renal: creatinine less than 2.5 mg/dl cardiovascular: no ongoing cardiac disease no new york heart association class iii or iv heart disease pulmonary: no ongoing pulmonary disease such as: asthma chronic obstructive pulmonary disease (copd) active radiation- or drug-induced pneumonitis other: not pregnant or nursing fertile patients must use effective contraception no history of autoimmune disease such as but not limited to: inflammatory bowel disease systemic lupus erythematosus ankylosing spondylitis scleroderma type i diabetes multiple sclerosis no other serious ongoing chronic or acute illness no medical or psychological impediment to study compliance no concurrent or prior second malignancy except: nonmelanoma skin cancer controlled superficial bladder cancer within the last 5 years no active or chronic infection including: urinary tract infection hiv viral hepatitis prior concurrent therapy: biologic therapy: no concurrent immunotherapy chemotherapy: no concurrent chemotherapy endocrine therapy: no concurrent corticosteroids no concurrent hormone therapy radiotherapy: no concurrent radiation therapy surgery: no specified other: no immunosuppressives such as: azathioprine cyclosporine a

Keywords: stage iv colon cancer lung metastases liver metastases
the effect of escitalopram on mood, quality of life and cognitive functioning in glioblastoma patients

Conditions: GBM; Depression

Summary: testing the effect of providing an antidepressant and anxiety-type escitalopram for patients with glioblastoma on patient's quality of life including the effect of treatment on mood and cognition during treatment.two subgroups will fill questionnaires : * questionnaire mini mental state exam (mmse) which is the maximum score of 30. a score of below 24 indicates a flaw in the level of dementia * questionnaire depression / mood phq9p(pa t i e n t h e a l t h qu e s t i o n n a i r e - 9) * the m. d. anderson symptom inventory (mdasi) * evaluation of the hospital situation awareness (clinical assessment and questionnaire) * cognitive assessment which will be carried out by the department neuropsychological and include: * executive function (stroop) * abstract reasoning (similarities) * -auditory and spatial attention (digit span, spatial span) visual memory and remembering literature * memory function - visual and auditory (rocf, ravlt) * language function: naming and verbal fluency * mindstreems neurotrax

this study is planned as prospective randomized, controlled, double-blind study. patients will undergo resection or biopsy of glioblastoma (newly diagnosed glioblastoma), will randomization ratio of 1: 1 by the pharmacist (by age,karnofsky score, extent of tumor resection), for two research groups: group number 1 will include 50 patients, who will receive escitalopram or placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months. . the dose study is fixed and is not aimed at symptomatic treatment of anti-depressant (such as major depression).

Eligibility criteria:
inclusion criteria:\* men and women * aged 18-80 * who signed an informed consent form * patients that underwent biopsy or resection of brain glioblastoma. * kps≥70 * patients that are stable in terms of seizures who take only one antiepileptic drug exclusion criteria: * patients who suffered from depression within five years, * patients treated with antidepressants * are not able to answer the questionnaires because of an inability to communicate * patients treated with inhibitors (maoi) such as: nialamide , isocarboxazid , iproniazid, phenerzine, tranylcypromine * patients who suffer from epilepsy. * patients who suffer from parkinson's * patients who suffer from cardiac dysfunction or heart attack recently. * patients with eye problems in expanding pupils - can result in the development of glaucoma and closed angle. * severe renal dysfunction. (creatinine clearance \<30 ml / min). , creatinine less than 1.5 times the upper limit of normal or end-stage renal disease * hepatic insufficiency -bilirubin general\> 1.5 times the upper limit of normal, hepatic enzymes less than 2.5 times upper limit of normal * pregnant women * a score of less than 24 test the mini-mental state examination (mmse) * allergy to any component of the drug- talc, croscarmellose sodium, microcrystalline cellulose silicified, magnesium stearate, hypromellose, macrogol 400, titanium dioxide
inside a neuron - ex vivo evaluation of cerebral and cerebellar neuronal activity.

Conditions: Human Neural Cells Functioning

Summary: understanding the functioning of human neurons has always been a key element, especially with regard to the translation of the inputs they receive into actions that determine human behavior. however, the vast majority of studies have been performed in animal models due to the difficulty in maintaining neuronal functions ex vivo. recently, techniques have been illustrated that allow us to obtain slices of brain tissue removed during neurosurgical interventions. the patch-clamp and hd-mea (high density - microelectrodes array) techniques, used until now for animal samples, can allow us to study the functioning of the neural cells that make up these slices. furthermore, the exploration of the functioning of the aforementioned cells in pathological conditions can open the field for further therapeutic perspectives.


Eligibility criteria:
inclusion criteria: * patients with a brain/cerebellum primary or secondary tumor for whom at least partial resection has been planned. exclusion criteria: * patients with a brain/cerebellum primary or secondary tumor for whom a biopsy has been planned

Keywords: insane, neurons, human, glioma, brain, patch-clamp, hd-mea
faith-based approaches in the treatment of hypertension (faith)

Conditions: Hypertension

Summary: the purpose of this study is to test the effect of a church-based lifestyle intervention on blood pressure reduction in 400 hypertensive blacks (bp\> 140/90 mm hg).

this study will test the effectiveness of a church-based lifestyle intervention in improving blood pressure control among 400 hypertensive blacks in a group randomized controlled trial. the lifestyle intervention will be delivered by trained lay health advisers through group-based behavioral counseling and motivational interviewing (mint-tlc) in 24 predominantly black churches in new york city.

Eligibility criteria:
inclusion criteria: * age 18 years or older * diagnosis of hypertension * self-identified black or african american * sbp \> 140 mmhg or dbp \> 90 mmhg (based on the average of 3 blood pressure readings); or average sbp \> 130 mm hg or dbp \> 80 mm hg (for those with diabetes or kidney disease) at the screening/baseline visits * able to speak english exclusion criteria: * unable to comply with the study protocol (either self-selected or by indicating during screening that s/he could not complete all requested tasks). * pregnancy

Keywords: motivational interviewing, lay health advisers
an eight-week study evaluating the efficacy and tolerability of two doses of ssr149415 in outpatients with major depressive disorder

Conditions: Depressive Disorder

Summary: the objective is to evaluate the efficacy and safety of two doses of ssr149415 (250 mg and 100 mg twice daily) compared to placebo and escitalopram 10 mg once daily in outpatients with major depressive disorder.


Eligibility criteria:
inclusion criteria: * diagnosis of major depressive disorder, as defined by dsm-iv criteria and confirmed by the semi-structured mini, recurrent episode. exclusion criteria: * total score of less than 24 on the madrs. * ham-d total score less than 18. * duration of the current depressive episode less than 1 month or greater than 2 years. * patients with a history or presence of bipolar disorders or psychotic disorders. * patients with alcohol dependence or abuse or substance dependence or abuse in the past 12 months except nicotine or caffeine dependence. * patients who have used the following prior to entry into acute phase: antipsychotics within 3 months, fluoxetine within 1 month, maois within 2 weeks, other antidepressants, anxiolytics, or mood-stabilizer (lithium, anticonvulsants) within 1 week except as allowed in the protocol. the investigator will evaluate whether there are other reasons why a patient may not participate

Keywords: depression antidepressive agents controlled clinical trial
ozone therapy and coronavirus disease of 2019 (covid-19) pneumonia

Conditions: COVID-19 Pneumonia

Summary: the objective is to determine whether the use of ozone autohemotherapy is associated with a decrease in time to clinical improvement


Eligibility criteria:
inclusion criteria: * confirmed covid-19 infection (diagnosed by nasopharyngeal swab performed on admission) * severe pneumonia with baseline chest x-ray abnormalities; * oxygen saturation \<94% on room air, and tachypnea with respiratory rate exceeding 30 per minute. * informed consent signed. exclusion criteria: * not willing to participate in the study.
skeletal muscle perfusion with lvad

Conditions: Heart Failure

Summary: advanced heart failure (when the heart pump fails) is associated with symptoms such as shortness of breath and extreme fatigue. some of these symptoms are simply due to failure of the pump, however abnormal regulation of blood flow to the muscles of the body is also a potential mechanism. left ventricular assist devices are mechanical pumps used to compensate for patients with failing hearts either as a bridge to heart transplant or as long term therapy. whether or not these pumps improve muscle flow and whether this is a determinant in the improvement of symptoms is unknown. understanding how skeletal muscle and heart perfusion is altered in heart failure patients before and after implantation of an lvad could provide further insight into the beneficial effects of this therapy. specific aims: 1. to evaluate skeletal muscle and heart perfusion studies before and after lvad implantation 2. to compare functional status with degree of skeletal muscle perfusion.

methods: thirty patients deemed to be candidates for lvad from either outpatient heart failure clinic or inpatient cardiology service will be studies. skeletal muscle perfusion imaging using standard of care ultrasound technology will be performed prior to lvad implant and then 3 months post implant. functional status by six minute walk test and specialized stress test will be assessed at 3 months post implant.

Eligibility criteria:
inclusion criteria: * patients deemed to be candidates for a lvad exclusion criteria: * severe peripheral artery disease * skeletal muscle disorder * severe congenital heart disease * pregnancy * patients \<18 yo

Keywords: left ventricular assist device contrast ultrasound perfusion imaging
a study of jnj-54767414 (daratumumab) in combination with lenalidomide and dexamethasone in japanese participants with previously untreated multiple myeloma who are ineligible for high-dose therapy and autologous stem cell transplantation

Conditions: Multiple Myeloma

Summary: the purpose of this study is to evaluate the safety of daratumumab when combined with lenalidomide and dexamethasone in japanese participants with newly diagnosed multiple myeloma who are not candidates for high-dose chemotherapy and autologous stem cell transplantation (asct).


Eligibility criteria:
inclusion criteria: * participants with documented multiple myeloma (mm) satisfying the crab (calcium elevation, renal insufficiency, anemia, and bone abnormalities) criteria , monoclonal plasma cells in the bone marrow more than equal to (\>=) 10 percent (%) or presence of a biopsy proven plasmacytoma, and measurable disease measurable disease as defined by any of the following: (a) immunoglobulin (ig) g mm: serum monoclonal paraprotein (m protein) level \>=1.0 gram/deciliter (dl) or urine m protein level \>= 200 milligram(mg)/24 hours; or (b) iga, igm, igd, or ige mm: serum m protein level \>=0.5 g/dl or urine m protein level \>=200 mg/24 hours; or (c) light chain mm without measurable disease in serum or urine: serum ig free light chain (flc) \>=10 mg/dl and abnormal serum ig kappa lambda flc ratio * participants newly diagnosed and not considered a candidate for high-dose chemotherapy with autologous stem cell transplantation (asct) due to being \>=65 years old, or in subjects less than (\<) 65 years old presence of important comorbid condition(s) likely to have a negative effect on the tolerability of high-dose chemotherapy with asct * pretreatment clinical laboratory values meeting the following criteria during the screening phase * participants must have an eastern cooperative oncology group (ecog) performance status score of 0 or 1 * a woman of childbearing potential must have 2 negative serum or urine pregnancy tests at screening, first within 4 weeks prior to dosing and the second within 3 days prior to dosing exclusion criteria: * participants with diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance, or smoldering mm * participant with plasma cell leukemia or other conditions in which ig (immunoglobulin) m protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions * participants who have prior or current systemic therapy or asct for mm, with the exception of an emergency use of a short course (equivalent of dexamethasone 40 mg/day for a maximum 4 days) of corticosteroids before treatment * participants with history of malignancy (other than mm) within 5 years before the date of the first daratumumab administration * participants who have radiation therapy within 14 days of the first dose
a cost analysis of interstim therapy

Conditions: Urinary Retention and Symptoms of Overactive Bladder (Urge, Frequency)

Summary: a study to examine the impact that interstim therapy for urinary control has on health care utilization and costs within a health care system and the satisfaction with treatment expressed by patients using this therapy.

a retrospective administrative data analysis combined with a prospective health related quality of life/satisfaction with treatment survey designed to examine the impact that interstim therapy for urinary control has had on health care utilization and costs for the kaiser permanente system and the satisfaction with treatment expressed by patients using this therapy.

Eligibility criteria:
patients implanted with an interstim therapy for urinary control or undergoing test stimulation for potential placement of interstim therapy during the period of june 1, 2002 through june 30, 2004 and who are enrolled with kaiser-permanente of southern california.
comparison of non-nutritive suck (nns) measures to clinical estimates of suck and feeding readiness in preterm infants

Conditions: Preterm Birth

Summary: this is a research study to quantitatively assess the development of non-nutritive suck (nns) and feeding readiness in preterm infants using a novel device, the ntrainer©, and to compare this with two clinical assessment tools, nomas and efs.

fifteen minutes before feeding, the mobile ntrainer recording station will be positioned cribside. following a brief exam of physiologic state, using the oral feeding readiness assessment portion of the efs, the infant will be cradled in a supportive inclined posture, swaddled, with limbs positioned at midline, and background/overhead lighting dimmed in the area to promote eye contact with the tester. sampling of nns behavior will not be initiated until the infant is in an optimal behavioral state, i.e., drowsy to active alert (state 3 or 4 or 5 as described by the naturalistic observation of newborn behavior, newborn individualized developmental care and assessment program; nidcap). the infant will be presented with the ntrainer pacifier, and several contiguous 30-second blocks of nns nipple compression data will be sampled using the neosuck rt software. the infant will remain connected to the usual nicu monitors at all times for observation of respiration, heartbeat and oxygen saturation. after the ntrainer data collection is completed, the baby will be fed by his or her nurse or parents as directed in the care plan. if the baby is able to feed by mouth, one of the investigators will observe the feeding, and perform 1) a nomas evaluation during the first 2 minutes of the feeding, and 2) an efs assessment after the feeding is completed. infants will be studied in 2 sessions each day beginning at day 4 to 7 of life, then twice weekly (2 sessions per day, 2 days per week) until hospital discharge.

Eligibility criteria:
inclusion criteria: * born at 30 to 36 weeks gestation and have no exclusion criteria. exclusion criteria: * significant birth defects. * breathing difficulties severe enough to require being on a ventilator or nasal cpap for more than 2 hours after birth. * any oxygen requirement at day 4 of life. * any neurologic problems, including seizures or frequent apnea spells.